NUDT15 and cervical carcinoma: To exclude the influence of different cancer type background, we performed experimental confirmation of the impact of NUDT15 expression on 6MP sensitivity in cell lines derived from PRCA (i.e., PC3, 22RV1) and cervical cancer (i.e., HeLa), where NUDT15 deletion is associated with a poor prognosis (Figure 2K).